Blood-Borne Diseases

Infectious disease specialists explain how long term international cooperation with impacted societies can help to stop the cycle of Ebola outbreaks.

How might this new outbreak in Mbandaka differ from the recent outbreak in Kivu, a more conflict-prone region of the DRC?

West and Central African nations have been developing infrastructure to combat ebola, malaria, malnutrition, and more.

In Mbandaka, an 11th outbreak of Ebola is emerging. This outbreak has renewed questions about what makes the virus such a challenge for Congolese society to reign in.

A modeling study from Imperial College shows the pandemic may have significant effect on mortality among other infectious disease patients.

The European Commission has granted Marketing Authorization for a 2-dose Ebola vaccine regimen.

A review of the latest infectious disease news.

As of June 1, there have been at least 6 cases of Ebola detected in Mbandaka, a port city with a population of more than 1.2 million people.

Investigators detailed a promising new approach to fighting malaria with an antibody that targets a specific malaria protein, triggering the pathogen to self-destruct.

A new case of Ebola has been confirmed in the city of Beni in the Democratic Republic of the Congo.

How has treating infections changed with the availability of experimental vaccines and therapeutics, and how can we apply this to COVID-19 today?

How does sharing needles impact the risk for hepatitis C among people who inject drugs?

The last confirmed patient with Ebola was discharged from care on March 4, 2020.

To assess available evidence and provide an update from the 2013 review, a team of investigators reviewed more than 80 studies featuring data from over 179,000 individuals.

PWID are unlikely to receive testing for HIV and hepatitis C, according to a new study that found that 8.5% were tested for HIV and 7.7% were tested for HCV within 1 year of a clinical encounter consistent with injection drug use.

The International Health Regulations Emergency Committee decided today that the Ebola outbreak in the Democratic Republic of the Congo remains a PHEIC.

A new article examines pregnancy outcomes among women who received the rVSV-ZEBOV vaccine in the STRIVE study.

Despite new treatment options with a lower theoretical risk, approximately 40% of patients with HCV experienced a drug-drug interaction.

Andrea L. Cox, MD, PhD, comments on the future of HCV vaccine development efforts in light of the 2019 trial which did not prevent chronic infection.

In this episode, our guests compare the West African Ebola outbreak to the ongoing outbreak in the Democratic Republic of the Congo.

Andrea L. Cox, MD, PhD, discusses some of the challenges in developing a vaccine for hepatitis C and details the results of a vaccine trial.

Investigators of a new analysis detail how Ebola case definitions became increasingly complex and discordant during the 6-month period in the countries surrounding the DRC.

A literature meta-analysis determined the worldwide prevalence of hepatitis B virus in people living with HIV.

Ervebo has been approved for the prevention of Ebola virus disease, caused by Zaire ebolavirus in individuals 18 years of age and older.

Ebola vaccines could be given as an emergency intervention to individuals exposed to the virus.